Targeting the ubiquitin-proteasome pathway in cancer therapy

Area of Science:

• Molecular biology
• Oncology
• Pharmacology

Background:

• The ubiquitin-proteasome pathway is crucial for protein degradation in cellular processes like apoptosis.
• Bortezomib is the first FDA-approved proteasome inhibitor for multiple myeloma, validating proteasome inhibition as an anticancer strategy.
• Preclinical studies show bortezomib's synergy with chemotherapy and ability to overcome drug resistance.

Purpose of the Study:

• To review the molecular mechanisms underlying bortezomib-induced apoptosis.
• To elucidate how bortezomib exerts its anti-tumor effects.

Main Methods:

• Literature review of preclinical and clinical studies on bortezomib.
• Analysis of molecular pathways affected by bortezomib, including NF-kappaB and endoplasmic reticulum stress.

Main Results:

• Bortezomib induces apoptosis through various pro-apoptotic pathways.
• Key mechanisms include inhibition of nuclear factor-kappaB (NF-kappaB) and induction of endoplasmic reticulum stress.
• Bortezomib demonstrates efficacy and safety in multiple myeloma treatment.

Conclusions:

• Bortezomib's anti-tumor activity is mediated by complex molecular mechanisms involving apoptosis induction.
• Further understanding of these mechanisms can optimize proteasome inhibitor-based cancer therapies.